Rüschoff, Josef R.

[["dc.bibliographiccitation.firstpage","550"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","British Journal of Surgery"],["dc.bibliographiccitation.lastpage","557"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Helms, H.-J."],["dc.contributor.author","Lordick, Florian"],["dc.contributor.author","Rueschoff, Josef"],["dc.contributor.author","Conradi, L.-C."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Liersch, Thorsten"],["dc.date.accessioned","2018-11-07T09:41:56Z"],["dc.date.available","2018-11-07T09:41:56Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Multidisciplinary discussion of the treatment of patients with colorectal liver metastases (CRLM) is advocated currently. The aim of this study was to investigate medical oncologists' and surgeons' assessment of resectability and indication for chemotherapy, and the effect of an educational intervention on such assessment. Methods: Medical histories of 30 patients with CRLM were presented to ten experienced medical oncologists and 11 surgeons at an initial virtual tumour board meeting (TB1). Treatment recommendations were obtained from each participant by voting for standardized answers. Following lectures on the potential of chemotherapy and surgery, assessment was repeated at a second virtual tumour board meeting (TB2), using the same patients and participants. Results: Overall, 630 answers (21 x 30) were obtained per tumour board meeting. At TB1, resectability was expected more frequently by surgeons. Participants changed 56.8 per cent of their individual answers at TB2. Assessment shifted from potentially resectable to resectable CRLM in 81 of 161 and from unresectable to (potentially) resectable CRLM in 29 of 36 answers. Preoperative chemotherapy was indicated more often by medical oncologists, and overall was included in 260 answers (41.3 per cent) at TB1, compared with only 171 answers (27.1 per cent) at TB2. Medical oncologists more often changed their decision to primary resection in resectable patients (P = 0.006). Postoperative chemotherapy was included in 51.9 and 52.4 per cent of all answers at TB1 and TB2 respectively, with no difference in changes between medical oncologists and surgeons (P = 0.980). Conclusion: Resectability and indication for preoperative chemotherapy were assessed differently by medical oncologists and surgeons. The educational intervention resulted in more patients deemed resectable by both oncologists and surgeons, and less frequent indication for chemotherapy."],["dc.description.sponsorship","Merck Serono GmbH, Germany"],["dc.identifier.doi","10.1002/bjs.9436"],["dc.identifier.isi","000332700100017"],["dc.identifier.pmid","24756914"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33842"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1365-2168"],["dc.relation.issn","0007-1323"],["dc.title","Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","522"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","American Journal of Surgical Pathology"],["dc.bibliographiccitation.lastpage","531"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Styczen, Hanna"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Roedel, Claus"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Talaulicar, Recca"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Rüschoff, Josef R."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:26:46Z"],["dc.date.available","2018-11-07T09:26:46Z"],["dc.date.issued","2013"],["dc.description.abstract","In patients with advanced rectal cancer (cUICC II and III) multimodality therapy resulted in better long-term local tumor control. Ongoing clinical trials are focusing on therapy intensification to improve disease-free (DFS) and cancer-specific survival (CSS), the integration of biomarkers for prediction of individual recurrence risk, and the identification of new targets. In this context, we investigated HER-2, a member of the epidermal growth factor receptor family, whose expression pattern and role was unclear in rectal cancer. A total of 264 patients (192 male, 72 female; median age 64 y) received standardized multidisciplinary treatment according to protocols of phase II/III trials of the German Rectal Cancer Study Group. HER-2 status was determined in pretherapeutic biopsies and resection specimens using immunohistochemistry scoring and detection of silver in situ hybridization amplification. Tumors with an immunohistochemistry score of 3(+) or silver in situ hybridization ratios of >= 2.0 were classified HER-2 positive; these results were correlated with clinicopathologic parameters [eg, resection (R) status, nodal status ((y)pN)], DFS, and CSS. Positive HER-2 status was found in 12.4% of biopsies and in 26.7% of resected specimens. With a median follow-up of 46.5 months, patients with HER-2 positivity showed in trend a better DFS (P = 0.1) and a benefit in CSS (P = 0.03). The 5-year survival rate was 96.0% (HER-2 positive) versus 80.0% (HER-2 negative). In univariate and multivariate analyses, HER-2 was an independent predictor for CSS (0.02) along with the (y)pN status (P < 0.00001) and R status (P = 0.011). HER-2 amplification is detectable in a relevant proportion (26.7%) of rectal cancer patients. For the development of innovative new therapies, HER-2 may represent a promising target and should be further assessed within prospective clinical trials."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft [KFO 179-2]"],["dc.identifier.doi","10.1097/PAS.0b013e318272ff4d"],["dc.identifier.isi","000316184000006"],["dc.identifier.pmid","23282976"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30374"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1532-0979"],["dc.relation.issn","0147-5185"],["dc.title","Frequency of HER-2 Positivity in Rectal Cancer and Prognosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","458"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Clinical Pathology"],["dc.bibliographiccitation.lastpage","464"],["dc.bibliographiccitation.volume","68"],["dc.contributor.author","Scheel, Andreas Hans"],["dc.contributor.author","Reineke, Rebecca A."],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Lokka, Suvi"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Rueschoff, Josef"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Middel, Peter"],["dc.date.accessioned","2018-11-07T09:56:45Z"],["dc.date.available","2018-11-07T09:56:45Z"],["dc.date.issued","2015"],["dc.description.abstract","Aims Acetone compression (AC) is an elution compression technique for the comprehensive pathological examination of fatty tissue. Here AC is combined with digital morphometry to evaluate the impact of preoperative (neoadjuvant) chemoradiotherapy (neoCRT) on lymph node (LN) numbers and morphology in locally advanced rectal cancer. AC is compared with complete embedding of the mesorectal fat (whole mesorectal embedding (WME)) to exclude artificial alterations and to the standard technique, manual dissectioning (MD). Methods 320 rectal cancer specimens were subjected to LN morphometry. Neoadjuvant CRT was applied in 204 specimens. LNs were prepared either with AC (n=138), WME (n=51) or MD (n=131). 8523 LNs were assessed including 530 nodes with metastases. Results LN prepared by AC and WME showed similar morphologies. AC revealed reduced LN sizes in neoCRT specimens compared with primary resection (2.2; 2.4 mm, p=0.049) while the LN number was comparable (27; 30/specimen). AC yielded 28 LN/specimen on average, MD yielded 22 LN (p<0.001). In neoCRT specimens, MD yielded less LN compared with primary resection (19; 25). MD detected less small LN (<2 mm; MD: 25%; AC: 56%) while 24 of the 135 LN metastases found by AC were <= 2 mm in diameter. Conclusions AC does not alter LN morphology and is especially suited to retrieve small LN after neoadjuvant CRT of rectal cancer. Neoadjuvant multimodality treatment caused reduced LN sizes while the LN numbers were not affected. When compared with MD, AC proved more reliable in the retrieval of LN from rectal cancer specimens after neoCRT."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft [KFO179]"],["dc.identifier.doi","10.1136/jclinpath-2014-202555"],["dc.identifier.isi","000354653500013"],["dc.identifier.pmid","25779094"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37025"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bmj Publishing Group"],["dc.relation.issn","1472-4146"],["dc.relation.issn","0021-9746"],["dc.title","Comprehensive lymph node morphometry in rectal cancer using acetone compression"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.lastpage","31"],["dc.bibliographiccitation.volume","34 Suppl 3"],["dc.contributor.author","Arnold, Dirk"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Hegewisch-Becker, Susanna"],["dc.contributor.author","Höhler, Thomas"],["dc.contributor.author","Knoefel, Wolfram Trudo"],["dc.contributor.author","Kubicka, Stefan"],["dc.contributor.author","Lang, Hauke"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Luster, Markus"],["dc.contributor.author","Oettle, Helmut"],["dc.contributor.author","Reinacher-Schick, Anke"],["dc.contributor.author","Ridwelski, Karsten"],["dc.contributor.author","Riess, Hanno"],["dc.contributor.author","Rödel, Claus"],["dc.contributor.author","Rüschoff, Josef"],["dc.contributor.author","Schmiegel, Wolff"],["dc.contributor.author","Schmoll, Hans-Joachim"],["dc.contributor.author","Vanhoefer, Udo"],["dc.date.accessioned","2019-07-09T11:53:49Z"],["dc.date.available","2019-07-09T11:53:49Z"],["dc.date.issued","2011"],["dc.description.abstract","Der XI. Interdisziplinäre Expertenworkshop «Gastrointestinale Tumore», an dem 19 Vertreter der Fachbereiche internistische Onkologie, Gastroenterologie, Strahlentherapie, Chirurgie, Nuklearmedizin und Pathologie teilnahmen, bot einen Überblick über den aktuellen Stand der Wissenschaft im Bereich der gastrointestinalen Karzinome, wobei der Schwerpunkt auf dem Kolon-/Rektum- und Magenkarzinom lag, da in diesen Bereichen die meisten neuen Entwicklungen zu verzeichnen waren. Der Workshop versteht sich als ein interaktives Diskussionsforum zur aktuellen Standortbestimmung von Diagnostik und Therapie sowie zur Thesengenerierung für neue wissenschaftliche und therapeutische Ansätze. Schwerpunkte der diesjährigen Veranstaltung waren zum einen die adjuvante Therapie des Kolonkarzinoms und die First-Line-Therapie des metastasierten kolorektalen Karzinoms, denn in diesen Indikationen haben neue Studiendaten jetzt eine weitere Klärung des Therapiealgorithmus herbeigeführt. Darüber hinaus war die perioperative Therapie bei Lebermetastasen ein wichtiges Thema, zu dem aktuelle Studienkonzepte vorgestellt wurden. Des Weiteren wurde die HER2- Diagnostik beim Magenkarzinom intensiv diskutiert, denn diese unterscheidet sich deutlich von der beim Mammakarzinom. Bei korrekter Diagnostik ist das HER2-positive Magenkarzinom offenbar deutlich weiter verbreitet als bisher angenommen. Viel Beachtung fanden auch die Ergebnisse von 2 aktuellen Phase-III-Studien beim Pankreaskarzinom, die das therapeutische Vorgehen verändern werden und erstmals seit langem einen Fortschritt bei diesem schwer therapierbaren Tumor bedeuten dürften. Die wichtigsten Ergebnisse der 2-tägigen Diskussionsrunde sind im vorliegenden Supplement zusammengefasst."],["dc.identifier.doi","10.1159/000328047"],["dc.identifier.fs","582631"],["dc.identifier.pmid","21577036"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8060"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60502"],["dc.language.iso","de"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1423-0240"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.mesh","Clinical Trials as Topic"],["dc.subject.mesh","Evidence-Based Medicine"],["dc.subject.mesh","Gastrointestinal Neoplasms"],["dc.subject.mesh","Humans"],["dc.subject.mesh","Interdisciplinary Studies"],["dc.subject.mesh","Medical Oncology"],["dc.title","Gastrointestinal tumors-interdisciplinary discussion over new data"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e101563"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","PLOS ONE"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Ilgen, Peter"],["dc.contributor.author","Stoldt, Stefan"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Wurm, Christian Andreas"],["dc.contributor.author","Rüschoff, Josef"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Jakobs, Stefan"],["dc.date.accessioned","2017-09-07T11:45:42Z"],["dc.date.available","2017-09-07T11:45:42Z"],["dc.date.issued","2014"],["dc.description.abstract","Formalin fixed and paraffin-embedded human tissue resected during cancer surgery is indispensable for diagnostic and therapeutic purposes and represents a vast and largely unexploited resource for research. Optical microscopy of such specimen is curtailed by the diffraction-limited resolution of conventional optical microscopy. To overcome this limitation, we used STED super-resolution microscopy enabling optical resolution well below the diffraction barrier. We visualized nanoscale protein distributions in sections of well-annotated paraffin-embedded human rectal cancer tissue stored in a clinical repository. Using antisera against several mitochondrial proteins, STED microscopy revealed distinct sub-mitochondrial protein distributions, suggesting a high level of structural preservation. Analysis of human tissues stored for up to 17 years demonstrated that these samples were still amenable for super-resolution microscopy. STED microscopy of sections of HER2 positive rectal adenocarcinoma revealed details in the surface and intracellular HER2 distribution that were blurred in the corresponding conventional images, demonstrating the potential of super-resolution microscopy to explore the thus far largely untapped nanoscale regime in tissues stored in biorepositories."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2014"],["dc.identifier.doi","10.1371/journal.pone.0101563"],["dc.identifier.gro","3142087"],["dc.identifier.isi","000339992400018"],["dc.identifier.pmid","25025184"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10481"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/4400"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","STED Super-Resolution Microscopy of Clinical Paraffin-Embedded Human Rectal Cancer Tissue"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Styczen, Hanna"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Nagelmeier, I."],["dc.contributor.author","Rüschoff, Josef R."],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:19:05Z"],["dc.date.available","2018-11-07T09:19:05Z"],["dc.date.issued","2013"],["dc.format.extent","118"],["dc.identifier.isi","000326360900284"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28551"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","1423-0240"],["dc.relation.issn","0378-584X"],["dc.title","HER-2 and HER-3 expression in locally advanced rectal cancer and metachronous metastases: new targets for treatment approaches?"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","26"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Cancer"],["dc.bibliographiccitation.lastpage","35"],["dc.bibliographiccitation.volume","119"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ermert, Heiko"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Rüschoff, Josef R."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Schueler, Philipp"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Roedel, Claus"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Roedel, Franz"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:30:52Z"],["dc.date.available","2018-11-07T09:30:52Z"],["dc.date.issued","2013"],["dc.description.abstract","BACKGROUND: The transmembrane glycoprotein CD133 (cluster of differentiation 133; also known as Prominin or PROM1) has been described as a potential stem cell marker in colorectal cancer and is associated with higher tumorigenic potential and resistance to radiochemotherapy (RCT). In this study, CD133 expression was evaluated in pre-RCT tumor biopsies and the corresponding post-RCT surgical specimens from patients with locally advanced rectal adenocarcinoma, and expression levels were correlated with histopathologic features and clinical follow-up. METHODS: One hundred twenty-six patients with International Union Against Cancer (UICC) stage II/III rectal cancer who received preoperative 5-fluorouracil (5-FU)-based RCT within the German Rectal Cancer Trials were investigated. Pre-RCT and post-RCT CD133 expression levels were determined using immunohistochemistry and were correlated with histopathologic parameters, tumor regression grade, cancer recurrence, and patient survival. RESULTS: Compared with pre-RCT biopsies, significantly higher CD133 expression was observed in tumor specimens (P = .01). However, no correlations were observed for either biopsies or tumor specimens between CD133 expression levels, histopathologic characteristics, or survival. In matched analyses of corresponding biopsy/tumor pairs, patients who had an increased fraction of CD133-expressing (CD133+) cells after preoperative RCT had significantly higher residual tumor stages (P = .02) and lower histopathologic tumor regression (P < .01). Moreover, these patients had significantly reduced disease-free survival and cancer-specific overall survival in univariate analysis (P < .001 and P = .004, respectively) and multivariate analysis (P = .003 and P = .024, respectively). CONCLUSIONS: The enrichment of CD133+ cancer cells during preoperative RCT was correlated with minor local tumor response, increased distant cancer recurrence, and decreased survival. The current results indicate that the up-regulation of intratumoral CD133 expression, in contrast to absolute pre-RCT and post-RCT CD133 levels, plays an important role in tumor progression and metastasis in patients with rectal cancer who are receiving neoadjuvant RCT. Cancer 2013. (c) 2012 American Cancer Society."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft [KFO 179]"],["dc.identifier.doi","10.1002/cncr.27703"],["dc.identifier.isi","000312543000007"],["dc.identifier.pmid","22736392"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31411"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","0008-543X"],["dc.title","Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","35589"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Gusky, Linda"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Müller-Dornieden, Annegret"],["dc.contributor.author","Schueler, Philipp"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Rüschoff, Josef R."],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Sax, Ulrich"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T10:06:58Z"],["dc.date.available","2018-11-07T10:06:58Z"],["dc.date.issued","2016"],["dc.description.abstract","Translational research relies on high-quality biospecimens. In patients with rectal cancer treated preoperatively with radiochemotherapy tissue based analyses are challenging. To assess quality challenges we analyzed tissue samples taken over the last years in a multicenter setting. We retrospectively evaluated overall 197 patients of the CAO/ARO/AIO-94- and 04-trial with locally advanced rectal cancer that were biopsied preoperatively at the University Medical Center Goettingen as well as in 10 cooperating hospitals in Germany. The cellular content of tumor, mucosa, stroma, necrosis and the amount of isolated DNA and RNA as well as the RNA integrity number (RIN) as quality parameters were evaluated. A high RNA yield (p = 2.75e-07) and the content of tumor (p = 0.004) is significantly associated to high RIN-values, whereas a high content of mucosa (p = 0.07) shows a trend and a high amount of necrosis (p = 0.01) is significantly associated with RNA of poor quality. Correlating biopsies from Goettingen and the cooperating centers showed comparable tumor content results. By taking small sized biopsies we could assess a clear correlation between a good RNA quality and a high amount of RNA and tumor cells. These results also indicate that specimens collected at different centers are of comparable quality."],["dc.identifier.doi","10.1038/srep35589"],["dc.identifier.isi","000385502600001"],["dc.identifier.pmid","27752113"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13950"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39196"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","2045-2322"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Neoadjuvant Therapy in Rectal Cancer - Biobanking of Preoperative Tumor Biopsies"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Rüschoff, Josef R."],["dc.contributor.author","Roedel, Claus"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Roedel, Franz"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:10:22Z"],["dc.date.available","2018-11-07T09:10:22Z"],["dc.date.issued","2012"],["dc.identifier.isi","000318009804886"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26473"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Chicago, IL"],["dc.title","Clinical significance and prognostic impact of CD133 expression in rectal cancer treated with preoperative radiochemotherapy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Styczen, Hanna"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Rüschoff, Josef R."],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:10:20Z"],["dc.date.available","2018-11-07T09:10:20Z"],["dc.date.issued","2012"],["dc.identifier.isi","000318009804672"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26462"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.eventlocation","Chicago, IL"],["dc.title","HER2 status in locally advanced rectal cancer and metachronous metastases: Opportunity for a new therapeutic approach?"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]